KURA on Nasdaq
Kura Oncology
In its 2026 annual report the company says: “We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.”5 It was founded in 2014.1 It is headquartered in La Jolla.1 Its shares trade on Nasdaq under the symbol KURA.1
Price unavailable
Last updated Oct 21, 2026.
Overview
2014Founded1
Compare with Zentalis Pharmaceuticals, Inc., Rockwell Medical Inc. or ENANTA PHARMACEUTICALS INC, or pick any stock.
- TickerKURA on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersLa Jolla1
- Websitewww.kuraoncology.com
- Incorporated inDE4
- Business address4930 Directors Place, Suite 500, San Diego, Ca 921214
- Filer categoryNon-accelerated filer, Smaller reporting company4
- Legal formCorporation3
- LEI5493005QORQTZCZYOP393
- StatusActive3
- LEI statusIssued and current3
- Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET, 19801 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 57055943
See how the biggest companies compare on our leaderboards
We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Our pipeline consists of small molecules designed to target cancer signaling pathways and address significant unmet needs in oncology and hematology.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-449.9%Operating margin6
-412.9%Net margin6
25.2%Revenue growth, 20256
-160.0%Return on equity6
0.06×Debt to equity6
-$70.7MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Collaboration revenue brought in 50% of the revenue Kura Oncology broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Collaboration revenue | $0 | $53.9M | $65.3M |
| Collaboration Revenue | $53.9M | $65.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development68¢$251.1M
- Selling, general and admin32¢$120.0M
- Income tax0¢$297.0K
Out of $67.5M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $67.5M | $53.9M | $0 |
| Cost of product sales | $57.0K | $0 | $0 |
| Research and development | $251.1M | $170.0M | $115.2M |
| Selling, general and administrative | $120.0M | $77.1M | $50.6M |
| Total operating expenses | $371.1M | $247.1M | $165.8M |
| Loss from operations | -$303.6M | -$193.2M | -$165.8M |
| Interest and other income, net | $26.8M | $22.8M | $14.7M |
| Interest expense | -$1.5M | -$1.6M | -$1.5M |
| Total other income, net | $25.3M | $21.2M | $13.2M |
| Loss before income taxes | -$278.4M | -$172.0M | -$152.6M |
| Income tax expense | $297.0K | $2.0M | $0 |
| Net Loss | -$278.7M | -$174.0M | -$152.6M |
| Net loss per share, basic | -$3.18 | -$2.02 | -$2.08 |
| Net loss per share, diluted | -$3.18 | -$2.02 | -$2.08 |
| Weighted average number of shares used in computing net loss per share, basic | 87.7M shares | 86.2M shares | 73.2M shares |
| Weighted average number of shares used in computing net loss per share, diluted | 87.7M shares | 86.2M shares | 73.2M shares |
| Unrealized gain on short-term investments | $260.0K | $2.0M | $6.8M |
| Comprehensive loss | -$278.4M | -$171.9M | -$145.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $149.1M | $224.5M | ||
| Short-term investments | $518.1M | $502.9M | ||
| Accounts receivable, net | $8.8M | $2.1M | ||
| Inventory | $413.0K | $0 | ||
| Prepaid expenses and other current assets | $32.2M | $15.4M | ||
| Total current assets | $708.7M | $744.8M | ||
| Property and equipment, net | $7.9M | $1.7M | ||
| Operating lease right-of-use assets | $7.3M | $5.8M | ||
| Other long-term assets | $14.5M | $7.8M | ||
| Total assets | $738.4M | $760.2M | ||
| Accounts payable | $5.0M | $1.5M | ||
| Accrued expenses and other current liabilities | $61.7M | $48.5M | ||
| Current operating lease liabilities | $1.3M | $1.9M | ||
| Current portion of long-term debt | $0 | $2.6M | ||
| Current portion of contract liabilities | $49.0M | $24.3M | ||
| Total current liabilities | $117.0M | $78.7M | ||
| Long-term debt, net of current portion | $9.7M | $6.9M | ||
| Long-term operating lease liabilities | $9.5M | $5.2M | ||
| Other long-term liabilities | $3.2M | $1.8M | ||
| Long-term contract liabilities | $424.9M | $253.9M | ||
| Total liabilities | $564.2M | $346.5M | ||
| Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $8.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive income | $1.0M | $764.0K | ||
| Accumulated deficit | -$1.2B | -$895.4M | ||
| Total stockholders' equity | $174.1M | $413.6M | $397.3M | $420.3M |
| Total liabilities and stockholders' equity | $738.4M | $760.2M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued | 87.9M shares | 78.2M shares | ||
| Common stock, shares outstanding | 87.9M shares | 78.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $149.1M | $224.5M | ||
| Short-term investments | $518.1M | $502.9M | ||
| Accounts receivable, net | $8.8M | $2.1M | ||
| Inventory | $413.0K | $0 | ||
| Prepaid expenses and other current assets | $32.2M | $15.4M | ||
| Total current assets | $708.7M | $744.8M | ||
| Property and equipment, net | $7.9M | $1.7M | ||
| Operating lease right-of-use assets | $7.3M | $5.8M | ||
| Other long-term assets | $14.5M | $7.8M | ||
| Total assets | $738.4M | $760.2M | ||
| Accounts payable | $5.0M | $1.5M | ||
| Accrued expenses and other current liabilities | $61.7M | $48.5M | ||
| Current operating lease liabilities | $1.3M | $1.9M | ||
| Current portion of long-term debt | $0 | $2.6M | ||
| Current portion of contract liabilities | $49.0M | $24.3M | ||
| Total current liabilities | $117.0M | $78.7M | ||
| Long-term debt, net of current portion | $9.7M | $6.9M | ||
| Long-term operating lease liabilities | $9.5M | $5.2M | ||
| Other long-term liabilities | $3.2M | $1.8M | ||
| Long-term contract liabilities | $424.9M | $253.9M | ||
| Total liabilities | $564.2M | $346.5M | ||
| Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $8.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive income | $1.0M | $764.0K | ||
| Accumulated deficit | -$1.2B | -$895.4M | ||
| Total stockholders' equity | $174.1M | $413.6M | $397.3M | $420.3M |
| Total liabilities and stockholders' equity | $738.4M | $760.2M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued | 87.9M shares | 78.2M shares | ||
| Common stock, shares outstanding | 87.9M shares | 78.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$278.7M | -$174.0M | -$152.6M |
| Share-based compensation expense | $37.1M | $33.9M | $28.1M |
| Amortization of premium and accretion of discounts on short-term investments, net | -$8.5M | -$13.1M | -$9.4M |
| Depreciation expense | $1.0M | $848.0K | $849.0K |
| Non-cash interest expense | $515.0K | $523.0K | $477.0K |
| Accounts receivable, net | -$6.7M | -$2.1M | $0 |
| Inventory | -$413.0K | $0 | $0 |
| Prepaid expenses and other current assets | -$15.9M | -$6.8M | -$2.0M |
| Accounts payable | $4.5M | -$1.6M | -$924.0K |
| Accrued expenses and other current liabilities | $12.7M | $16.8M | $11.3M |
| Operating lease right-of-use and other long-term assets | -$6.4M | $947.0K | -$685.0K |
| Other long-term liabilities | $1.0M | $758.0K | $137.0K |
| Contract liabilities | $195.7M | $278.2M | $0 |
| Net cash (used in) provided by operating activities | -$64.1M | $134.3M | -$124.8M |
| Purchases of short-term investments | -$761.6M | -$659.0M | -$409.8M |
| Maturities of short-term investments | $755.1M | $557.9M | $425.5M |
| Purchases of property and equipment | -$6.6M | -$472.0K | -$168.0K |
| Net cash (used in) provided by investing activities | -$13.1M | -$101.6M | $15.6M |
| Proceeds from issuance of stock under equity plans | $1.8M | $8.6M | $1.2M |
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | $0 | $145.8M | $93.6M |
| Net cash provided by financing activities | $1.8M | $154.4M | $94.8M |
| Net (decrease) increase in cash and cash equivalents | -$75.4M | $187.1M | -$14.5M |
| Interest paid | $998.0K | $1.1M | $1.1M |
No quarter-by-quarter statement was filed.
Corporate structure
Kura Oncology sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Kura Oncology
- MONTANOVA CAPITAL, LLC Filed SCHEDULE 13G/A on Kura Oncology, latest Aug 14, 2026 (7 filings since Dec 9, 2021)
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Kura Oncology, latest May 15, 2026 (6 filings since Feb 14, 2025)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Kura Oncology, latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Kura Oncology, latest Mar 27, 2026 (3 filings since Feb 9, 2023)
- State Street Corporation Filed SCHEDULE 13G on Kura Oncology, latest Feb 9, 2026 (4 filings since Feb 11, 2022)
- BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13G/A on Kura Oncology, latest Nov 14, 2025 (7 filings since Dec 5, 2022)
- EcoR1 Capital, LLC Filed SCHEDULE 13G/A on Kura Oncology, latest Aug 14, 2025 (4 filings since Jan 31, 2022)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on Kura Oncology, latest May 15, 2025 (2 filings since Dec 5, 2024)
- BlackRock Filed SCHEDULE 13G/A on Kura Oncology, latest Apr 17, 2025 (5 filings since Feb 3, 2022)
- Paradigm Biocapital Advisors LP Filed SCHEDULE 13G/A on Kura Oncology, latest Feb 14, 2025 (3 filings since May 2, 2024)
- James E. Flynn Filed SCHEDULE 13G/A on Kura Oncology, latest Feb 13, 2025 (5 filings since Dec 3, 2021)
- Avoro Capital Advisors LLC Filed SC 13G/A on Kura Oncology, latest Feb 14, 2023
- Kura Oncology La Jolla, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Kura Oncology reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $10.8M6 Dec 31, 2025 | $5.0M6 Dec 31, 2024 | +117.0% |
| Accumulated depreciation | $2.9M6 Dec 31, 2025 | $3.3M6 Dec 31, 2024 | −11.5% |
| Property and equipment, net | $7.9M6 Dec 31, 2025 | $1.7M6 Dec 31, 2024 | +367.0% |
| Operating-lease assets (leased space) | $7.3M6 Dec 31, 2025 | $5.8M6 Dec 31, 2024 | +25.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $149.1M6 Dec 31, 2025 | $224.5M6 Dec 31, 2024 | −33.6% |
| Marketable securities, current | $518.1M6 Dec 31, 2025 | $502.9M6 Dec 31, 2024 | +3.0% |
Inventory
Properties, in its own words
We occupy approximately 32,512 square feet of office space for our corporate headquarters in San Diego, California under a lease that expires in May 2033. We also occupy approximately 16,541 square feet of office space in Boston, Massachusetts under a lease that expires in July 2031.
Item 2 of the 10-K filed Mar 5, 2026.5
Leadership
Who has led Kura Oncology, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerTroy Edward Wilson Mar 16, 2015 to now14
- PresidentTroy Edward Wilson Mar 16, 2015 to now14
- PresidentJohn Pappajohn Apr 4, 2008 to Mar 10, 201515
- Chief financial officerJennifer Fulk Sep 10, 2026 to now16
- Chief financial officerMarc Grasso Aug 22, 2018 to Jan 28, 202217
- Chief financial officerHeidi Henson Mar 16, 2015 to Jan 26, 201818
- Chief financial officerMatthew P. Kinley Apr 4, 2008 to Mar 10, 201519
- Chief operating officerKathleen Ford Aug 13, 2019 to now20
- Chief operating officerJohn Farnam Jul 3, 2018 to Jan 24, 201921
Board members and other officers (23)
- Chief Scientific OfficerFrancis Burrows Jan 7, 2025 to now22
- Chief Medical OfficerMollie Leoni Jan 7, 2025 to now23
- Chief Commercial OfficerBrian T. Powl Aug 16, 2023 to now24
- Chief Commercial OfficerKirsten Flowers Jan 7, 2020 to Jan 31, 202325
- Acting Chief Medical OfficerBridget A. Martell Feb 12, 2020 to Dec 15, 202026
- Chief Medical OfficerStephen Dale Aug 25, 2020 to Jan 31, 202427
- Chief Medical OfficerAntonio Gualberto Mar 16, 2015 to Jul 12, 201928
- SVP, ChemistryPingda Ren Mar 16, 2015 to Jan 24, 201929
- Board memberMichael Vasconcelles Sep 17, 2024 to now30
- Board memberCarol Schafer Jun 4, 2021 to now31
- Board memberHelen Louise Collins Jul 29, 2021 to now32
- Board memberDiane L. Parks Oct 16, 2019 to now33
- Board memberMary T. Szela Nov 8, 2018 to now34
- Board memberSteven H. Stein Jan 3, 2017 to Jun 23, 202235
- Board memberTroy Edward Wilson Mar 16, 2015 to now14
- Board memberRobert Hoffman Mar 26, 2015 to Jun 23, 202136
- Board memberFaheem Hasnain Apr 27, 2015 to now37
- Board memberThomas Malley Oct 14, 2015 to now38
- Board memberJohn Pappajohn Apr 4, 2008 to Mar 10, 201515
- Board memberMatthew P. Kinley Apr 4, 2008 to Mar 10, 201519
- General counselTeresa Brophy Bair Oct 19, 2021 to now39
- General counselJames Basta Nov 5, 2019 to Jan 28, 202140
- General counselAnnette North Mar 16, 2015 to Jan 24, 201941
Former names
- ZETA ACQUISITION CORP IIIFeb 1, 2008 to Mar 10, 20154
Timeline
- Sep 9, 20268-K Other events42
- Sep 8, 20268-K Executive or director change43
- Aug 12, 20268-K Results of operations44
- Jul 29, 20268-K Executive or director change45
- Jun 4, 20268-K Executive or director change; Shareholder vote46
- May 12, 20268-K Results of operations47
- Mar 5, 20268-K Results of operations48
- Jan 29, 20268-K Bylaws or fiscal year changed49
- Jan 12, 20268-K Results of operations50
- Dec 2, 20258-K Other events51
- Nov 13, 20258-K Other events52
- Nov 4, 20258-K Results of operations53
- Mar 16, 2015New chief executive Troy Edward Wilson becomes CEO14
- 2014Founded Founded1
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.85) a share, on Nov 4, 2025.54
When it reported results
- Aug 12, 2026Reported quarterly or annual results44
- May 12, 2026Reported quarterly or annual results47
- Mar 5, 2026Reported quarterly or annual results48
- Jan 12, 2026Reported quarterly or annual results50
- Nov 4, 2025Reported quarterly or annual results53
- Aug 7, 2025Reported quarterly or annual results55
- May 1, 2025Reported quarterly or annual results56
- Feb 26, 2025Reported quarterly or annual results57
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
358 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 62 major events, 138 insider forms, 52 large holders, 1 private raises, 85 other. The latest 20:
- Sep 29, 2026144 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 25, 20264 EDGAR
- Sep 24, 2026144 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20263 EDGAR
- Sep 9, 20268-K EDGAR
- Sep 8, 20268-K EDGAR
The 358 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
63 open-market trades by officers, directors and large owners since October 2021: 6 buys and 57 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | FORD KATHLEENChief Operating Officer | Sale | 3,668 | $10.75 | $39.4K | Form 4 |
| Sep 29, 2026 | Leoni MollieChief Medical Officer | Sale | 28,802 | $10.75 | $309.6K | Form 4 |
| Sep 29, 2026 | Powl Brian T.Chief Commercial Officer | Sale | 15,430 | $10.75 | $165.9K | Form 4 |
| Sep 28, 2026 | Bair Teresa BrophyChief Legal Officer | Sale | 8,442 | $10.50 | $88.6K | Form 4 |
| Sep 28, 2026 | FORD KATHLEENChief Operating Officer | Sale | 6,906 | $10.50 | $72.5K | Form 4 |
| Sep 28, 2026 | Leoni MollieChief Medical Officer | Sale | 12,448 | $10.50 | $130.7K | Form 4 |
| Sep 28, 2026 | DOYLE THOMAS JAMESSVP, Finance & Accounting | Sale | 4,607 | $10.50 | $48.4K | Form 4 |
| Sep 28, 2026 | Powl Brian T.Chief Commercial Officer | Sale | 17,020 | $10.53 | $179.2K | Form 4 |
| Sep 24, 2026 | Burrows FrancisChief Scientific Officer | Sale | 20,726 | $10.83 | $224.5K | Form 4 |
| Aug 24, 2026 | WILSON TROY EDWARDPresident and CEO | Buy | 100,000 | $12.39 | $1.2M | Form 4 |
| Aug 21, 2026 | Powl Brian T.Chief Commercial Officer | Sale | 4,345 | $11.89 | $51.7K | Form 4 |
| Aug 19, 2026 | Bair Teresa BrophyChief Legal Officer | Sale | 31,487 | $12.63 | $397.7K | Form 4 |
| Aug 17, 2026 | WILSON TROY EDWARDPresident and CEO | Buy | 100,000 | $11.12 | $1.1M | Form 4 |
| Jun 18, 2026 | Leoni MollieChief Medical Officer | Sale | 84,929 | $9.82 | $834.0K | Form 4 |
| May 21, 2026 | Powl Brian T.Chief Commercial Officer | Sale | 10,000 | $11.00 | $110.0K | Form 4 |
| May 19, 2026 | FORD KATHLEENChief Operating Officer | Sale | 2,257 | $9.08 | $20.5K | Form 4 |
| May 19, 2026 | Powl Brian T.Chief Commercial Officer | Sale | 339 | $9.21 | $3.1K | Form 4 |
| May 18, 2026 | Bair Teresa BrophyChief Legal Officer | Sale | 2,256 | $9.38 | $21.2K | Form 4 |
| Jan 27, 2026 | Burrows FrancisChief Scientific Officer | Sale | 1,311 | $8.46 | $11.1K | Form 4 |
| Jan 27, 2026 | Powl Brian T.Chief Commercial Officer | Sale | 6,414 | $8.46 | $54.3K | Form 4 |
All 63 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- MONTANOVA CAPITAL, LLCSCHEDULE 13G/A, 7 filings Dec 9, 2021 to Aug 14, 202658
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 6 filings Feb 14, 2025 to May 15, 202659
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202660
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Feb 9, 2023 to Mar 27, 202661
- State Street CorporationSCHEDULE 13G, 4 filings Feb 11, 2022 to Feb 9, 202662
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 7 filings Dec 5, 2022 to Nov 14, 202563
- EcoR1 Capital, LLCSCHEDULE 13G/A, 4 filings Jan 31, 2022 to Aug 14, 202564
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 2 filings Dec 5, 2024 to May 15, 202565
- BlackRockSCHEDULE 13G/A, 5 filings Feb 3, 2022 to Apr 17, 202566
- Paradigm Biocapital Advisors LPSCHEDULE 13G/A, 3 filings May 2, 2024 to Feb 14, 202567
- James E. FlynnSCHEDULE 13G/A, 5 filings Dec 3, 2021 to Feb 13, 202568
- Avoro Capital Advisors LLCSC 13G/A, 1 filing Feb 14, 202369
- Deep Track Capital, LPSC 13G/A, 2 filings Feb 4, 2022 to Feb 14, 202370
- FMR LLCSC 13G/A, 2 filings Jan 10, 2022 to Mar 10, 202271
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Troy E. WilsonPh.D., J.D. | $700.0K | $4.7M72 | |
| 2025 | Brian Powl | 52 | $506.3K | $2.7M72 |
| 2025 | Kathleen Ford | 79 | $539.9K | $1.9M72 |
| 2024 | President and Chief Executive Officer | $671.7K | $6.2M72 | |
| 2024 | Chief Operating Officer | $519.2K | $2.5M72 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $150.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2024 | $150.0M | $150.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | $115.3M | 0.0% | +871,702 |
| Montanova Capital, LLC | 8,575,422 | $94.1M | 2.0% | No change |
| Bvf Inc/il | 8,445,769 | $92.7M | 2.4% | No change |
| State Street Corp | 5,329,208 | $58.5M | 0.0% | +817,317 |
| Vanguard Capital Management LLC | 3,916,164 | $43.0M | 0.0% | +130,479 |
| Armistice Capital, LLC | 3,678,000 | $40.3M | 1.1% | −58,000 |
| Aqr Capital Management LLC | 3,126,727 | $34.3M | 0.0% | +1,002,247 |
| Goldman Sachs Group Inc | 2,265,171 | $24.8M | 0.0% | +831,700 |
| Geode Capital Management, LLC | 2,229,958 | $24.5M | 0.0% | +195,682 |
| Alethea Capital Management, LLC | 2,167,938 | $23.8M | 9.9% | +638,569 |
| Prosight Management, LP | 2,021,964 | $22.2M | 3.8% | −1,334,736 |
| Deep Track Capital, LP | 1,978,565 | $21.7M | 0.3% | −664,977 |
| Renaissance Technologies LLC | 1,663,765 | $18.3M | 0.0% | +81,197 |
| Arrowstreet Capital, Limited Partnership | 1,410,275 | $15.5M | 0.0% | New |
| Vanguard Portfolio Management LLC | 1,329,941 | $14.6M | 0.0% | +99,139 |
| Nan Fung Trinity (hk) Ltd | 1,174,880 | $12.9M | 1.3% | +110,000 |
| Qube Research & Technologies Ltd | 1,169,884 | $12.8M | 0.0% | −466,849 |
| Dimensional Fund Advisors LP | 1,169,189 | $12.8M | 0.0% | −256,756 |
| Bank Of America Corp /de/ | 1,160,921 | $12.7M | 0.0% | −69,210 |
| Morgan Stanley | 1,160,310 | $12.7M | 0.0% | −3,667 |
| Connor, Clark & Lunn Investment Management Ltd. | 996,114 | $10.9M | 0.0% | +195,517 |
| UBS Group AG | 964,636 | $10.6M | 0.0% | −75,597 |
| Jacobs Levy Equity Management, Inc | 948,974 | $10.4M | 0.0% | +346,743 |
| Northern Trust Corp | 831,160 | $9.1M | 0.0% | +74,887 |
| Millennium Management LLC | 711,332 | $7.8M | 0.0% | −853,811 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Dec 12, 2022 | Christopher L. Jacobs, House | Buy | $1,001 - $15,000 | −119.8% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Kura Oncology is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARKura Oncology, Inc.2
- CIK0001422143
- Employer ID (EIN)61-15478515
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address4930 Directors Place, Suite 500, San Diego, CA 921212
- Phone(858) 500-88002
- Shares outstanding88,960,619 as of Aug 7, 202612
- Public float$496.1M as of Jun 30, 20255
- AuditorErnst & Young LLP, San Diego, CA USA PCAOB ID 42; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceFeb 1, 20082
- Filings805 in all: 4 (237), 8-K (149), SC 13G/A (61), 10-Q (54), 144 (48), 3 (33), SC 13G (24), 10-K (18)2
All 43 form types
424B5 (18), 424B3 (16), S-8 (16), SCHEDULE 13G/A (16), CORRESP (14), DEFA14A (12), CT ORDER (11), DEF 14A (11), EFFECT (9), UPLOAD (8), S-3 (6), SCHEDULE 13G (5), ARS (4), 5 (3), S-1/A (3), SC 13D (3), 10QSB (2), 8-K/A (2), D (2), PRE 14A (2), S-1 (2), S-3/A (2), S-3ASR (2), 10SB12G (1), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DEF 14C (1), POS AM (1), POS EX (1), PRE 14C (1), S-3MEF (1), SC 14F1 (1)
- Latest filingsAnnual report (10-K) Mar 5, 2026
Quarterly report (10-Q) Aug 12, 2026
Proxy statement (DEF 14A) Apr 10, 2026
Latest 8-K (8-K) Sep 9, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.0001 per share | KURA | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 5, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Kura Oncology names in Item 1A of its 10-K filed Mar 5, 2026: 72 risks under these headings, as written.5
- Risks Related to the Commercialization of KOMZIFTI and Our Product Candidates
- Our ability to generate revenue is highly dependent on the successful commercialization of KOMZIFTI in the United States and continued global development of ziftomenib. If we are unable to successfully commercialize KOMZIFTI in the United States, or to expand ziftomenib’s indications of use or market opportunity, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.
- KOMZIFTI may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- If the market opportunities for KOMZIFTI are smaller than we believe, our revenue may be adversely affected, and our business may suffer.
- If we are unable to execute on our sales, marketing and distribution plans to commercialize KOMZIFTI, we may be unable to generate meaningful product revenue.
- If competitors develop products, product candidates or technologies that are superior to or more favorable than KOMZIFTI or our product candidates, such development would significantly impact the development and commercial viability of KOMZIFTI and our product candidates, which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.
- Post-approval results for KOMZIFTI in larger numbers of patients, broader populations or real world clinical practice may not be consistent with the results from our clinical trials.
- We have limited experience as a commercial company and our sales, marketing and distribution of KOMZIFTI may be unsuccessful or less successful than anticipated.
- The insurance coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain coverage and adequate reimbursement for KOMZIFTI or any product candidates for which we receive marketing approval could limit our ability to market those products and decrease our ability to generate revenue.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of KOMZIFTI or any other approved products.
- Risks Related to Regulatory Approval of Our Product and Product Candidates and Other Legal Compliance Matters
- We may be unable to maintain FDA approval of KOMZIFTI for adult patients with relapsed or refractory NPM1-mutated AML, which would severely and adversely affect our business and business prospects.
The other 61 risks
- If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals in some or all planned regions, whether due to actual or perceived deficiencies in our applications, changes in regulatory requirements, evolving agency guidance or interpretation, resource constraints at regulatory authorities, or other factors, we will not be able to commercialize, or may be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.
- Our marketing approval for KOMZIFTI in the United States for adult patients with relapsed or refractory NPM1-mutated AML is subject to post-approval regulatory requirements and commitments, and we may be subject to penalties, restrictions or withdrawal from the market if we fail to comply with these requirements and commitments or if we experience unanticipated problems with KOMZIFTI.
- Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.
- Although the FDA has granted Orphan Drug Designation to ziftomenib for the treatment of AML, we may not be able to obtain orphan drug exclusivity, and even if obtained, such exclusivity may not effectively protect ziftomenib from competition, which could limit the potential profitability of ziftomenib.
- Our relationships with healthcare professionals, customers and third-party payors and our general business operations are subject to applicable fraud and abuse laws, including anti-kickback and false claims laws, transparency laws, privacy laws and other healthcare laws and regulations, which could expose us to significant penalties, including criminal sanctions, administrative and civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties.
- Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates and commercialize our products, and may affect the prices we may obtain.
- Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
- Risks Related to the Discovery and Development of Our Product Candidates
- Our discovery, preclinical and clinical development activities are primarily focused on the development of targeted therapeutics for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs may not lead to new marketable products or new approved disease indications.
- Clinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of subsequent clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
- We anticipate that our current product candidates and any future product candidates may be used in combination with third-party drugs or biologics, some of which may still be in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.
- Our product candidates may cause serious adverse events or have unacceptable side effects that could delay, limit or prevent their development.
- Failure by us or our third-party collaborators to develop, validate and obtain regulatory approval for a diagnostic testing platform could harm our drug development strategy and operational results.
- We may find it difficult to enroll patients in our clinical trials. Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates.
- We may expend our limited resources to pursue a specific product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- Risks Related to Our Financial Position and Need for Additional Capital
- We have incurred losses since our inception, expect to incur losses over the next several years and may never achieve or maintain profitability.
- We have limited historical product revenue, and we expect that our financial and operating results will vary significantly from period to period.
- We may need to obtain substantial additional capital in connection with our continuing operations. If we are required to raise additional capital, doing so may cause dilution to our stockholders, restrict our operations or require us to relinquish certain rights to our technologies or product candidates.
- Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions could adversely affect our current financial condition and projected business operations.
- Risks Related to Our Dependence on Third Parties
- Our collaboration with Kyowa Kirin is important to our business. If Kyowa Kirin ceases development efforts under the Kyowa License Agreement, or if the Kyowa License Agreement is terminated, we may not receive future milestone payments or royalties under the Kyowa License Agreement and our business could be adversely affected. If Kyowa Kirin does not fulfill its obligations under the Kyowa Co-Promotion Agreement, our business could be adversely affected.
- We rely on third-party contractors and organizations to conduct, and/or to supply materials to conduct, our clinical trials and provide commercial supply, and those third parties may not perform satisfactorily, including failing to meet deadlines for the supply of materials and/or the completion of such clinical trials or to meet the demands of our commercial supply.
- We depend on third parties for the manufacture of our product candidates for preclinical and clinical testing and for the manufacture of commercial supplies of KOMZIFTI. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or KOMZIFTI at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts.
- Risks Related to Our Intellectual Property
- If we are unable to, or if we do not, obtain and maintain intellectual property protection for our product and product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product and product candidates may be impaired.
- We depend on our licensors to prosecute and maintain patents and patent applications that are material to our business. Any failure by our licensors to effectively protect these intellectual property rights could adversely impact our business and operations.
- Patent terms may be inadequate to protect our competitive position on our product and product candidates for a commercially meaningful length of time.
- We may not be successful in obtaining or maintaining necessary third-party intellectual property rights for our development pipeline through acquisitions and in-licenses.
- If we are unable to maintain the confidentiality of our trade secrets or other confidential information, our business and competitive position would be harmed.
- If we breach any of the agreements under which we license from third parties the development and/or commercialization rights to our product candidates, we could lose license rights that are important to our business and our operations could be materially harmed.
- The patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position.
- Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product and product candidates.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
- Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
- Intellectual property discovered through government-funded programs may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for use of U.S.-based manufacturing companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.
- We may not be able to protect our intellectual property rights throughout the world.
- Risks Related to Employee Matters, Managing Growth and Macroeconomic Conditions
- We are highly dependent on our Chief Executive Officer. Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
- We have expanded our development, regulatory, operations, medical affairs, and commercial capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
- Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
- If our information technology systems, or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
- Our business and operations would suffer in the event of system failures.
- Actual or threatened public health epidemics or outbreaks may adversely impact our industry, including our clinical trials, our supply chain, our liquidity and access to capital markets and our business development activities.
- Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity and other events beyond our control, the occurrence of which could materially harm our business.
- International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business, financial condition, results of operations and prospects.
- Risks Related to Ownership of our Common Stock
- Our stock price may fluctuate significantly and you may have difficulty selling your shares based on current trading volumes of our stock.
- The price of our common stock may be volatile and may be influenced by numerous factors, some of which are beyond our control.
- We have broad discretion in the use of our cash and may not use our cash effectively, which could adversely affect our results of operations.
- FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock.
- The resale of shares covered by our effective shelf registration statements could adversely affect the market price of our common stock in the public market, which result would in turn negatively affect our ability to raise additional equity capital.
- We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our operating results.
- If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors’ views of us.
- We are a “smaller reporting company” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.
- Future sales and issuances of our common stock or rights to purchase or acquire common stock, including pursuant to our equity incentive plans, outstanding stock options, restricted stock units, performance-based restricted stock units, warrants, pre-funded warrants or otherwise, could result in dilution to the percentage ownership of our stockholders and could cause our stock price to fall.
- Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
- Our charter documents provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
- Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.
- We do not intend to pay cash dividends on our capital stock in the foreseeable future.
- General Risk Factors
- If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us, our business or our market, our stock price and trading volume could decline.
- Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.
- Securities class action litigation could divert our management’s attention and harm our business and could subject us to significant liabilities.
Legal proceedings
We are not currently a party to, nor is our property the subject of, any material legal proceedings.
The opening of Item 3, Legal Proceedings.5
Links
- Websitewww.kuraoncology.com1
- X (Twitter)x.com/kuraoncology1
- WikidataQ30269121
- SEC EDGARCIK 1422143
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataKura Oncology on Wikidata
- 2SEC EDGARKura Oncology filings on SEC EDGAR
- 3
- 4SEC EDGARKura Oncology filings on SEC EDGAR
- 5
- 6SEC EDGARKura Oncology 10-K for fiscal 2025
- 7SEC EDGARKura Oncology 10-K for fiscal 2022
- 8SEC EDGARKura Oncology 10-K for fiscal 2019
- 9SEC EDGARKura Oncology 10-K for fiscal 2020
- 10SEC EDGARKura Oncology 10-K for fiscal 2021
- 11SEC EDGARKura Oncology 10-Q for fiscal 2026
- 12SEC EDGARKura Oncology 10-Q for fiscal 2026
- 13SEC EDGARKura Oncology 10-K for fiscal 2019
- 14
- 15SEC EDGARJohn Pappajohn, President
- 16
- 17SEC EDGARMarc Grasso, Chief financial officer
- 18
- 19
- 20
- 21SEC EDGARJohn Farnam, Chief operating officer
- 22
- 23SEC EDGARMollie Leoni, Chief Medical Officer
- 24
- 25
- 26
- 27SEC EDGARStephen Dale, Chief Medical Officer
- 28
- 29SEC EDGARPingda Ren, SVP, Chemistry
- 30SEC EDGARMichael Vasconcelles, Board member
- 31SEC EDGARCarol Schafer, Board member
- 32SEC EDGARHelen Louise Collins, Board member
- 33SEC EDGARDiane L. Parks, Board member
- 34SEC EDGARMary T. Szela, Board member
- 35SEC EDGARSteven H. Stein, Board member
- 36SEC EDGARRobert Hoffman, Board member
- 37SEC EDGARFaheem Hasnain, Board member
- 38SEC EDGARThomas Malley, Board member
- 39SEC EDGARTeresa Brophy Bair, General counsel
- 40SEC EDGARJames Basta, General counsel
- 41SEC EDGARAnnette North, General counsel
- 42SEC EDGAROther events
- 43SEC EDGARExecutive or director change
- 44SEC EDGARResults of operations
- 45SEC EDGARExecutive or director change
- 46
- 47SEC EDGARResults of operations
- 48SEC EDGARResults of operations
- 49SEC EDGARBylaws or fiscal year changed
- 50SEC EDGARResults of operations
- 51SEC EDGAROther events
- 52SEC EDGAROther events
- 53SEC EDGARResults of operations
- 54NasdaqNasdaq calendar
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71SEC EDGARFMR LLC SC 13G/A on Kura Oncology
- 72
- 73